\
&
Contact us
\
&
Contact us
Published on | 3 years ago
Programmes Enhancing EU R&I Horizon EuropeA call for proposals is open for the new recognition prize EU Award for Gender Equality Champions. The prize is meant to:
There are three prize categories:
Candidates can only apply to one of these three categories. Applicants can be a university, higher education institution, or research performing organisation (public or private) located in an EU Member State or a country associated to Horizon Europe.
Deadline for applications is 13 October 2022 at 17.00 (CET). Winners receive a prize of 100.000 euro. In the Sustainable Gender Equality Champions category two winners will be awarded a prize. Winners will be announced before the end of 2022 (HE WIDERA work programme 2021-2022, p.154-156).
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Research Infrastructures Horizon Europe Digital Europe
Building on the revised Charter for access to research infrastructures , this new Charter will be specifically aimed at facilitating access of companies. It will make it easier for companies, especially small and medium-sized businesses (SMEs), startups and scaleups, to access Europe’s world-class research and technology... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
